- Home
- SCSC vs XNCR Comparison
SCSC vs XNCR Comparison
Compare SCSC & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCSC | XNCR |
|---|---|---|
| Founded | 1992 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 881.9M |
| IPO Year | 1997 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SCSC | XNCR |
|---|---|---|
| Price | $49.63 | $12.64 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $43.00 | $22.33 |
| AVG Volume (30 Days) | 188.2K | ★ 611.2K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $3,846,260,000.00 | $125,576,000.00 |
| Revenue This Year | $2.60 | N/A |
| Revenue Next Year | $4.01 | $4.80 |
| P/E Ratio | $20.47 | ★ N/A |
| Revenue Growth | 7.79 | ★ 13.65 |
| 52 Week Low | $33.76 | $6.92 |
| 52 Week High | $50.64 | $18.69 |
Technical Indicators
Market Signals| Indicator | SCSC | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 65.20 | 57.92 |
| Support Level | $39.44 | $12.19 |
| Resistance Level | N/A | $12.65 |
| Average True Range (ATR) | 1.67 | 0.60 |
| MACD | -0.04 | 0.14 |
| Stochastic Oscillator | 81.28 | 69.71 |
Price Performance
Historical ComparisonAbout SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Intelisys & Advisory Segment. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States and Canada, and also has its presence in Brazil, and other countries.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.